hemophilia A

Bleeding disorders: When to worry, how to helpStudies have shown that 1 in 5 women who consult their doctor for heavy or prolonged bleeding during their periods actually have an underlying bleeding disorder.
New antibody eases hemophilia treatmentA new antibody eases treatment of severe hemophilia A.
FDA approves Bayer hemophilia A drugFDA recently approved antihemophilic factor VIII (recombinant) (Kovaltry, Bayer) for the treatment of hemophilia A in children and adults.
FDA OKs modified antihemophilic factor for hemophilia AFDA has approved recombinant, PEGlyated Antihemophilic Factor (Adynovate, Baxalta) for use in patients who have Hemophilia A.
FDA approves Obizur for acquired hemophilia AFDA has approved Antihemophilic Factor (Recombinant), Porcine Sequence] (Obizur, Baxter) for the treatment of bleeding episodes in adults with acquired hemophilia A.
FDA drug approvals - October 2014
FDA drug approvals - October 2014FDA actions in brief, fast-track designations, priority review.
FDA drug approvals-July 2014FDA drug approvals, priority review, breakthrough designation, fast-track designations, orphan drug designations, first-time generic approval
FDA approves first hemophilia A drug to extend interval between prophylactic infusions in adults and childrenFDA has approved Antihemophilic Factor (Recombinant), Fc Fusion Protein (Eloctate, Biogen Idec) for the control and prevention of bleeding episodes, perioperative (surgical) management and routine prophylaxis in adults and children with hemophilia A.
FDA drug approvals-June 2014FDA actions in brief, breakthrough therapy designations, fast-track designations, first-time generic approval
FDA approves antihemophilic factor VIII for hemophilia AFDA has approved a new indication for antihemophilic factor VIII (recombinant), (Kogenate FS, Bayer), for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults with hemophilia A.